Medical Affairs Reputations (EU5): Type 2 Diabetes Mellitus

Medical Affairs Reputations (EU5): Type 2 Diabetes Mellitus

Code: FW-20150905 | Published: Sep-2015 | Pages: - | FirstWord
Price :

* Required Fields



What do physicians think of Europe Medical Affairs teams in the Type 2 Diabetes Mellitus (T2DM) sector? Who gets top marks for performance and reputation? Who fails to measure up? How is your Medical Affairs team impacting your relationship with customers?

To find out, we surveyed 150 physicians from across the continent regarding ten leading T2DM products and their associated Medical Affairs teams.

What did they have to say about your team? Are you lagging or leading your competitors?

Order your report now to find out.

Note that in addition to the Europe report we offer an equivalent report for the U.S. Order both and receive, at no cost, a third report clearly setting out the differences in findings between the two regions.

Answering key questions

- What Medical Affairs offerings do physicians most value, and how well is your team providing them?
- Whose Medical Affairs teams are most respected, and how exactly do they distinguish themselves from the pack?
- Do physicians feel they hear from your Medical Affairs team as much as theyd like to, and what media and methods do they prefer?
- What does gap analyses reveal about your Medical Affairs team versus your competitors?
- Where is your Medical Affairs team succeeding and where are there opportunities for improvement?

Emerging Themes:

Medical Affairs teams in T2DM are generally well received, but physicians do have several recommendations for improvement; we provide the details.

Some Medical Affairs offerings are highly desired by physicians. Others generate much less interest. We let you know where your team might make adjustments and strengthen relationships as a result.

The products leading in the marketplace dont necessarily lead in Medical Affairs. Which teams are doing their T2DM products justice? Which might be dragging them down?

This report lets you know.

Products Included in the Report:

- AstraZeneca
- Forxiga (dapagliflozin)
- Boehringer Ingelheim
- Jardiance (empagliflozin)
- Eli Lilly
- Trulicity (dulaglutide)
- GlaxoSmithKline
- Eperzan (albiglutide)
- Johnson & Johnson
- Invokana (canagliflozin)
- Merck & Co.
- Januvia (sitagliptin)
- Novartis
- Galvus (vildagliptin)
- Novo Nordisk
- Tresiba (insulin degludec)
- Sanofi
- Toujeo (insulin glargine)
- Takeda
- Vipidia (alogliptin)

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your companys success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
Learn more at

Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]

2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal

3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at


There are no reports matching the selection.

Browse similar reports by category:
Pharmaceuticals & Healthcare

Our Clients